Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Lisata Therapeutics (LSTA) over the last 13 years, with Q3 2025 value amounting to $4.4 million.

  • Lisata Therapeutics' Operating Expenses fell 1727.89% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year decrease of 995.1%. This contributed to the annual value of $23.4 million for FY2024, which is 894.27% down from last year.
  • According to the latest figures from Q3 2025, Lisata Therapeutics' Operating Expenses is $4.4 million, which was down 1727.89% from $4.9 million recorded in Q2 2025.
  • Lisata Therapeutics' Operating Expenses' 5-year high stood at $6.9 million during Q2 2023, with a 5-year trough of $4.4 million in Q3 2025.
  • For the 3-year period, Lisata Therapeutics' Operating Expenses averaged around $5.8 million, with its median value being $5.9 million (2024).
  • Data for Lisata Therapeutics' Operating Expenses shows a peak YoY increase of 126.14% (in 2024) and a maximum YoY decrease of 1966.55% (in 2024) over the last 5 years.
  • Over the past 3 years, Lisata Therapeutics' Operating Expenses (Quarter) stood at $6.0 million in 2023, then decreased by 1.26% to $5.9 million in 2024, then fell by 25.8% to $4.4 million in 2025.
  • Its Operating Expenses stands at $4.4 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.8 million for Q1 2025.